Drug Trial Radar · NCT04771130
A Study of BGB-11417 in Participants With Myeloid Malignancies
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
May 24, 2021
Primary completion
Aug 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Feb 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasm
Interventions
BGB-11417Drug
Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
AzacitidineDrug
Intravenous or subcutaneous administration for 7 days.
PosaconazoleDrug
Oral administration for 8 days on second cycle only.
BGB-11417Drug
Oral administration for 28 days on a 28-day cycle.
BGB-11417Drug
Oral administration for 10, 14 or 21 days on a 28-day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs)
- Part 1 And 2: Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Approximately 24 months
- Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) RateTime frame: Approximately 24 months
- Part 3 MDS Cohort: Modified Overall Response (mOR) RateTime frame: Approximately 24 months
- Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to the last quantifiable timepoint (t) (AUC0-t) Of BGB-11417 When Administered Alone and when Co-administered With PosaconazoleTime frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)
- Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Administered Alone and When Co-administered With PosaconazoleTime frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)
- Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to infinity (AUC0-infinity) Of BGB-11417 When Administered Alone and When Co-administered With PosaconazoleTime frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, , 4, 6, 8, and 24 hours postdose)
- Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number Of Participants Experiencing DLTsTime frame: Cycle 2
- Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number of Participants Experiencing TEAEsTime frame: Approximately 24 months
Locations
47 sites in 10 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Terminated
Tampa General Hospital
Tampa, Florida · Recruiting
Upmc Hillman Cancer Center(Univ of Pittsburgh)
Pittsburgh, Pennsylvania · Recruiting
Md Anderson Cancer Center
Houston, Texas · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Concord Repatriation General Hospital
Concord, New South Wales, Australia · Recruiting
St George Hospital
Kogarah, New South Wales, Australia · Recruiting
Orange Health Hospital
Orange, New South Wales, Australia · Recruiting
Gold Coast University Hospital
Southport, Queensland, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Fiona Stanley Hospital
Murdoch, Western Australia, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
One Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Peking University Peoples Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Hospital of Lanzhou University
Lanzhou, Gansu, China · Recruiting
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, China · Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Recruiting
The Second Peoples Hospital of Shenzhen
Shenzhen, Guangdong, China · Completed
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Completed
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Hopital Claude Huriez Chu Lille
Lille, France · Recruiting
Hopital Larchet
Nice, France · Recruiting
Hopital Saint Louis
Paris, France · Recruiting
Universitaetsklinikum Leipzig Aor
Leipzig, Germany · Recruiting
Universitaetsklinikum Ulm
Ulm, Germany · Recruiting
Policlinico Sorsola Malpighi, Aou Di Bologna
Bologna, Italy · Recruiting
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
Meldola, Italy · Recruiting
Niguarda Cancer Center Division of Hematology
Milan, Italy · Recruiting
North Shore Hospital
Auckland, New Zealand · Recruiting
Aotearoa Clinical Trials
Auckland, New Zealand · Recruiting
Wellington Regional Hospital (Ccdhb)
Wellington, New Zealand · Recruiting
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, South Korea · Recruiting
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.